Severe Rifampicin-Induced Immune Thrombocytopenia During Treatment of Cavitary Pulmonary Tuberculosis: A Case Report
Abstract
Rifampicin is first-line therapy for drug-susceptible tuberculosis (TB) but rarely causes severe immune-mediated thrombocytopenia, which may be overlooked amid multiple concomitant medications. A 49-year-old man with cavitary pulmonary TB developed severe thrombocytopenia nine days after starting rifampicin-containing therapy; platelets fell abruptly from 311,000/µL to 9,000/µL. He also received prophylactic heparin, vancomycin, and other antimicrobials. The 4Ts score indicated low probability of heparin-induced thrombocytopenia, and peripheral smear excluded microangiopathic processes. Rifampicin-induced immune thrombocytopenia (RIT) was diagnosed based on temporal association, exclusion of major alternatives, and rapid platelet recovery after rifampicin discontinuation. RIT should be considered in acute severe thrombocytopenia during TB treatment, even with other thrombocytopeniaassociated drugs. Early recognition and prompt withdrawal of the offending agent are essential to reduce bleeding risk and permit continuation of effective TB therapy with an alternative regimen.
https://doi.org/10.1517/14740338.5.2.231
[2] Lee SW, Park Y, Song JH, et al. Rifampicin-induced thrombocytopenia: a case report and literature review. Korean
J Intern Med. 2009;24(2):143-6. https://doi.org/10.3904/kjim.2002.17.2.143
[3] Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med. 2007;357(6):580-7. https://doi.org/10.1056/NEJMra066469
[4] Pedersen-Bjergaard U, Andersen M, Hansen PB. Drug-induced thrombocytopenia: clinical data on 309 cases and the effect of corticosteroid therapy. Eur J Clin Pharmacol. 1997;52(3):183-9. https://doi.org/10.1007/s002280050272
[5] Dixit R, George J, Sharma AK. Thrombocytopenia due to rifampicin. Lung India. 2012;29(1):90-2. https://doi.
org/10.4103/0970-2113.92380
[6] Verma AK, Singh A, Chandra A, Kumar S, Gupta RK. Rifampicin-induced thrombocytopenia. Indian J Pharmacol.
2010;42(4):240-2. https://doi.org/10.4103/0253-7613.68432
[7] Aster RH, Curtis BR, McFarland JG, Bougie DW. Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management. J Thromb Haemost. 2009;7(6):911-8. https://doi.org/10.1111/j.1538-7836.2009.03360.x
[8] George JN, Aster RH. Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. Hematology
Am Soc Hematol Educ Program. 2009:153-8. https://doi.org/10.1182/asheducation-2009.1.153
[9] Koumpis E, Papathanasiou K, Papakonstantinou I, Tassi I, Serpanou A, Kapsali E, et al. Rifampicin-induced
thrombocytopenia: a case report and short review of the literature. Eur Med J (Chelmsf). 2021. https://doi.
org/10.33590/emj/20-00193
[10] Nakane C, Nishimoto K, Kishimoto E, Suzuki K, Nakagawa E, Morikawa M, et al. A case of severe thrombocytopenia
after the first exposure to rifampicin. Respir Med Case Rep. 2023;42:101823. https://doi.org/10.1016/j.rmcr.2023.101823
[11] Batt J, Khan K. Responsible use of rifampin for the treatment of latent tuberculosis infection. CMAJ. 2019;191(25):E678-9. https://doi.org/10.1503/cmaj.190081
[12] Kim HJ, Lee YJ, Song MJ, Kwon BS, Kim YW, Lim SY, et al. Realworld experience of adverse reactions-necessitated rifampicinsparing treatment for drug-susceptible pulmonary tuberculosis. Sci Rep. 2023;13(1):11275. https://doi.org/10.1038/s41598-023-38394-1
[13] Boddu R, Sharma A, Mishra K, Kumar S. Rifampicin-induced thrombocytopenia in a patient with abdominal tuberculosis. Ann Natl Acad Med Sci (India). 2024;60:26-9. https://doi.org/10.25259/ANAMS-2022-3-9-(585)
[14] Rai R, Adityan J. Thrombocytopenia induced by intermittent therapy with Rifampicin - a case report. Lepr Rev. 2018;89:170- 2. https://doi.org/10.47276/lr.89.2.170
| Files | ||
| Issue | Vol 11 No 4 (2026): July-August | |
| Section | Case Report(s) | |
| Keywords | ||
| Rifampin Immune thrombocytopenia Drug side effect Pulmonary tuberculosis | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |

